Ipilimumab vs Osimertinib

## Ipilimumab vs Osimertinib: Overview

This comparison examines the pharmacological differences between **Ipilimumab** and **Osimertinib**.

## Mechanism of Action

**Ipilimumab**: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.

**Osimertinib**: Third-generation irreversible EGFR TKI targeting T790M resistance mutation and activating mutations.

## Pharmacokinetics

**Half-life**: Ipilimumab — 14.7 days; Osimertinib — 48 hours.

## Chemical Properties

**Molecular Formula**: Ipilimumab — N/A; Osimertinib — C28H33N7O2.

**Molecular Weight**: Ipilimumab — N/A; Osimertinib — 499.6050 g/mol.

**Type**: Ipilimumab — Antibody; Osimertinib — Small molecule.